Journal of Microbiology

Journal Articles

Endophytic bacterial and fungal microbiota in different cultivars of cassava (Manihot esculenta Crantz): Hong Li , Chengliang Yan , Yanqiong Tang , Xiang Ma , Yinhua Chen , Songbi Chen , Min Lin , Zhu Liu; J. Microbiol. 2020;58(7):614-623. Published online May 18, 2020; DOI: https://doi.org/10.1007/s12275-020-9565-x

77 View
0 Download
14 Web of Science
12 Crossref

Endophytes colonize tissues of healthy host plants and play a crucial role in plant growth and development. However, little attention has been paid to the endophytes of tuber crops such as cassava, which is used as a staple food by approximately 800 million people worldwide. This study aimed to elucidate the diversity and composition of endophytic bacterial and fungal communities in different cassava cultivars using high-throughput sequencing. Although no significant differences in richness or diversity were observed among the different cassava cultivars, the community compositions were diverse. Two cultivars (SC124 and SC205) tolerant to root rot exhibited similar community compositions, while two other cultivars (SC10 and SC5), which are moderately and highly susceptible to root rot, respectively, harboured similar community compositions. Proteobacteria, Firmicutes, and Ascomycota dominated the endophyte assemblages, with Weissella, Serratia, Lasiodiplodia, Fusarium, and Diaporthe being the predominant genera. The differentially abundant taxonomic clades between the tolerant and susceptible cultivars were mainly rare taxa, such as Lachnoclostridium_5, Rhizobium, Lampropedia, and Stenotrophomonas. These seemed to be key genera that affected the susceptibility of cassava to root rot. Moreover, the comparison of KEGG functional profiles revealed that ‘Environmental adaptation’ category was significantly enriched in the tolerant cultivars, while ‘Infectious diseases: Parasitic’ category was significantly enriched in the susceptible cultivars. The present findings open opportunities for further studies on the roles of endophytes in the susceptibility of plants to diseases.

Citations

Citations to this article as recorded by

Are rot-causing Botryosphaeriaceae species surviving in healthy Manihot esculenta propagative material in Brazil?
Amanda Cupertino de Queiroz Brito, Juliana Ferreira de Mello, José Vitorino da Silva Neto, Daniele Magna Azevedo de Assis, Ana Elisa de Almeida Souza, Antonio Félix da Costa, Ueder Pedro Lopes, Cristina Maria de Souza-Motta, Alexandre Reis Machado
Tropical Plant Pathology.2025;[Epub] CrossRef
Nutrient Management Under Good Agricultural Practices for Sustainable Cassava Production in Northeastern Thailand
Derrick Keith Thompson, Ornprapa Thepsilvisut, Phanawan Imorachorn, Saowakol Boonkaen, Preuk Chutimanukul, Suthasinee Somyong, Wuttichai Mhuantong, Hiroshi Ehara
Resources.2025; 14(3): 39. CrossRef
Impact of Vanadium–Titanium–Magnetite Mining Activities on Endophytic Bacterial Communities and Functions in the Root Systems of Local Plants
Zhuang Xiong, Yunfeng Zhang, Xiaodie Chen, Ajia Sha, Wenqi Xiao, Yingyong Luo, Lianxin Peng, Liang Zou, Qiang Li
Genes.2024; 15(5): 526. CrossRef
Colorimetric LAMP Assay for Detection of Xanthomonas phaseoli pv. manihotis in Cassava Through Genomics: A New Approach to an Old Problem
Ian C. Bispo Carvalho, Alice Maria Silva Carvalho, Adriane Wendland, Maurício Rossato
Plant Disease.2024; 108(10): 2993. CrossRef
Genetic diversity, plant growth promotion potential, and antimicrobial activity of culturable endophytic actinobacteria isolated from Aconitum carmichaelii Debeaux
Lan Zou, Yaopeng Zhang, Qian Wang, Siyu Wang, Muyi Li, Jing Huang
Journal of Applied Microbiology.2023;[Epub] CrossRef
High-throughput sequencing-based analysis of the composition and diversity of endophytic bacteria community in tubers of Gastrodia elata f.glauca
Heng Zheng, Peng Zhang, Jing Qin, Jiani Guo, Jun Deng
Frontiers in Microbiology.2023;[Epub] CrossRef
Richness of Nigrospora spp. (Apiosporaceae) in Manihot esculenta in Brazil and the description of three new species
Amanda Cupertino de Queiroz Brito, Juliana Ferreira de Mello, Ana Elisa de Almeida Souza, Sandy dos Santos Nascimento, Cristina Maria de Souza-Motta, Alexandre Reis Machado
Mycological Progress.2023;[Epub] CrossRef
Biocontrol de Fusarium spp. en el cultivo de vainilla: Un nuevo modelo de estudio
Laura Steffania Franco-Galindo , Ana Teresa Mosquera-Espinosa
Temas Agrarios.2023; 28(1): 95. CrossRef
Endophytic bacterial community structure and diversity of the medicinal plant Mirabilis himalaica from different locations
Erhao Zhang, Yazhou Lu, Rundong Zhao, Xiu Yin, Jie Zhang, Benxia Yu, Min Yao, Zhihua Liao, Xiaozhong Lan
Brazilian Journal of Microbiology.2023; 54(4): 2991. CrossRef
Diversity of the Bacterial Microbiome Associated With the Endosphere and Rhizosphere of Different Cassava (Manihot esculenta Crantz) Genotypes
Jingwen Ha, Yu Gao, Rui Zhang, Ke Li, Yijie Zhang, Xiaolei Niu, Xin Chen, Kai Luo, Yinhua Chen
Frontiers in Microbiology.2021;[Epub] CrossRef
The Diversity of Culture-Dependent Gram-Negative Rhizobacteria Associated with Manihot esculenta Crantz Plants Subjected to Water-Deficit Stress
Tatiana Zapata, Diana Marcela Galindo, Alba Rocío Corrales-Ducuara, Iván Darío Ocampo-Ibáñez
Diversity.2021; 13(8): 366. CrossRef
Isolation and characterization of cassava root endophytic bacteria with the ability to promote plant growth and control the in vitro and in vivo growth of Phytopythium sp.
Solange da Cunha Ferreira, Alessandra Keiko Nakasone, Silvia Mara Coelho do Nascimento, Danyllo Amaral de Oliveira, Andrei Santos Siqueira, Elisa Ferreira Moura Cunha, Gledson Luiz Salgado de Castro, Cláudia Regina Batista de Souza
Physiological and Molecular Plant Pathology.2021; 116: 101709. CrossRef

IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation: Min-Hye Park , Ji Won You , Hyoung Jin Kim , Hong-Jin Kim; J. Microbiol. 2019;57(9):821-827. Published online August 27, 2019; DOI: https://doi.org/10.1007/s12275-019-9308-z

58 View
0 Download
4 Web of Science
4 Crossref

Abstract

Most commercialized virus-like particle (VLP) vaccines use aluminum salt as adjuvant, even though VLPs provoke adequate antibody responses without adjuvant. We do not have detailed knowledge of how adjuvant affects the profile of anti- VLP antibodies. Meanwhile, there is evidence that differences between vaccination protocols influence the glycosylation of antibodies, which may alter their effector functions. In the present study a murine model was used to investigate the effects of dosing schedule and adjuvant on the antibody profiles and glycosylation levels of antigen-specific antibody responses to human papillomavirus type 16 L1 (HPV16 L1) VLPs. Mice received subcutaneously 2,000 ng of antigen divided into 4 or 7 doses. The HPV16 L1 VLPs elicited > 4 log10 anti-HPV16 L1 IgG titers without adjuvant, and aluminum hydroxide as adjuvant increased IgG titers 1.3- to 4-fold and reduced the anti-HPV16 L1 IgG2a / anti-HPV16 L1 IgG1 ratio value (use of aluminum hydroxide reduced the ratio of the IgG2a). Immunization with HPV16 L1 VLPs in combination with Freund’s adjuvant enhanced IgG titers 5- to 12- fold. Seven-dose immunization markedly increased anti- HPV16 L1 IgM titers compared to four-dose immunization, as well as increasing the proportion of glycosylated antibodies. Our results suggest that antibody glycosylation can be controlled immunologically, and IgG and IgM profiles and glycosylation profiles of the vaccine-induced antibodies can be used as indicators reflecting the vaccine characteristics. These
results
indicate that the HPV16 L1 VLP dosing schedule can affect the quality of antigen-specific antibody responses. We suggest that dosing schedules should be noted in vaccination protocols for VLP-based vaccines.

Citations

Citations to this article as recorded by

Human papillomavirus vaccines: organisation and experience of preclinical studies
A. S. Korovkin, T. N. Nikitina, T. Yu. Kozlova, D. V. Gorenkov, A. R. Volgin
Biological Products. Prevention, Diagnosis, Treatment.2024; 24(3): 243. CrossRef
Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice
Sima Sazegari, Malihe Akbarzadeh Niaki, Alireza Afsharifar, Ali Niazi, Abdollah Derakhshandeh, Maryam Moradi Vahdat, Farshad Hemmati, Mohammad Hadi Eskandari
Microbial Cell Factories.2023;[Epub] CrossRef
Anti-JMH alloantibody in inherited JMH-negative patients leads to immunogenic destruction of JMH-positive RBCs
Zhaohu Yuan, Yaming Wei, Xiaojie Chen, Shufei He, Kui Cai, Minglu Zhong, Huiying Huang, Xinxin Tong, Zhen Liu, Xuexin Yang
Clinical and Experimental Immunology.2021; 205(2): 182. CrossRef
Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women
Elham Hassen, Devendra Bansal, Randa Ghdira, Anouar Chaieb, Hedi Khairi, Abdelfattah Zakhama, Sami Remadi, Johan Hoebeke, Ali A. Sultan, Lotfi Chouchane
Journal of Translational Medicine.2020;[Epub] CrossRef

Review

REVIEW] Exploiting virus-like particles as innovative vaccines against emerging viral infections: Hotcherl Jeong , Baik Lin Seong; J. Microbiol. 2017;55(3):220-230. Published online February 28, 2017; DOI: https://doi.org/10.1007/s12275-017-7058-3

52 View
0 Download
52 Crossref

Abstract

Emerging viruses pose a major threat to humans and livestock with global public health and economic burdens. Vaccination remains an effective tool to reduce this threat, and yet, the conventional cell culture often fails to produce sufficient vaccine dose. As an alternative to cell-culture based vaccine, virus-like particles (VLPs) are considered as a highpriority vaccine strategy against emerging viruses. VLPs represent highly ordered repetitive structures via macromolecular assemblies of viral proteins. The particulate nature allows efficient uptake into antigen presenting cells stimulating both innate and adaptive immune responses towards enhanced vaccine efficacy. Increasing research activity and translation opportunity necessitate the advances in the design of VLPs and new bioprocessing modalities for efficient and cost-effective production. Herein, we describe major achievements and challenges in this endeavor, with respect to designing strategies to harnessing the immunogenic potential, production platforms, downstream processes, and some exemplary
case
s in developing VLP-based vaccines.

Citations

Citations to this article as recorded by

Harnessing Pentameric Scaffold of Cholera Toxin B (CTB) for Design of Subvirion Recombinant Dengue Virus Vaccine
Jemin Sung, Yucheol Cheong, Young-Seok Kim, Jina Ahn, Myung Hyun Sohn, Sanguine Byun, Baik-Lin Seong
Vaccines.2024; 12(1): 92. CrossRef
Global progress in clinical research on human respiratory syncytial virus vaccines
Ruofan Peng, Chenghao Chen, Qian Chen, Yuwen Zhang, Renjin Huang, Yanjun Zhang, Jianhua Li
Frontiers in Microbiology.2024;[Epub] CrossRef
Virus-like particles in poultry disease: an approach to effective and safe vaccination
Abdullahi Abdullahi Raji, Paniz Zarghami Dastjerdi, Abdul Rahman Omar
Frontiers in Veterinary Science.2024;[Epub] CrossRef
Sf9 Cell Metabolism Throughout the Recombinant Baculovirus and Rabies Virus-Like Particles Production in Two Culture Systems
Luis Giovani Oliveira Guardalini, Jaci Leme, Paulo Eduardo da Silva Cavalcante, Renata Gois de Mello, Thaissa Consoni Bernardino, Simone Gonçalves Silva Jared, Marta Maria Antoniazzi, Renato Mancini Astray, Aldo Tonso, Eutimio Gustavo Fernández Núñez, Sor
Molecular Biotechnology.2024; 66(2): 354. CrossRef
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview
Ruth Henríquez, Isabel Muñoz-Barroso
Heliyon.2024; 10(15): e34927. CrossRef
Design and Application of Biosafe Coronavirus Engineering Systems without Virulence
Guoqiang Wu, Qiaoyu Li, Junbiao Dai, Guobin Mao, Yingxin Ma
Viruses.2024; 16(5): 659. CrossRef
Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers Matter
Sara Molenda, Agata Sikorska, Anna Florczak, Patryk Lorenc, Hanna Dams-Kozlowska
Cancers.2023; 15(23): 5647. CrossRef
Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
Vartika Srivastava, Kripa N. Nand, Aijaz Ahmad, Ravinder Kumar
Vaccines.2023; 11(2): 479. CrossRef
Viral protein-based nanoparticles (part 2): Pharmaceutical applications
Rocio Mellid-Carballal, Sara Gutierrez-Gutierrez, Carmen Rivas, Marcos Garcia-Fuentes
European Journal of Pharmaceutical Sciences.2023; 189: 106558. CrossRef
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants
Nicola Principi, Giovanni Autore, Serafina Perrone, Susanna Esposito
Expert Opinion on Pharmacotherapy.2023; 24(6): 747. CrossRef
Viral Nanoparticles‐Mediated Delivery of Therapeutic Cargo
Saba Zanganeh, Mohammad Doroudian, Zohreh R. Nowzari, Pourya Nasirmoghadas, Javid Sadri Nahand, Shima Sepehrpour, Mohsen Moghoofei
Advanced Therapeutics.2023;[Epub] CrossRef
Emerging Trends and Future Challenges of Nanovaccine Delivery via Nasal Route
Hitesh Kumar Dewangan, Akash Raghuvanshi, Kamal Shah
Current Drug Targets.2023; 24(3): 261. CrossRef
A Virus-like Particle-Based F4 Enterotoxigenic Escherichia coli Vaccine Is Inhibited by Maternally Derived Antibodies in Piglets but Generates Robust Responses in Sows
Kara-Lee Aves, Priscila R. Guerra, Ana H. Fresno, Mauro M. S. Saraiva, Eric Cox, Poul J. Bækbo, Morten A. Nielsen, Adam F. Sander, John E. Olsen
Pathogens.2023; 12(12): 1388. CrossRef
Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application
Lei Zhang, Wen Xu, Xi Ma, XiaoJing Sun, JinBo Fan, Yang Wang
Biotechnology and Bioprocess Engineering.2023; 28(1): 1. CrossRef
Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications
Ernesto Garay, Diego Fontana, Lautaro Leschiutta, Ricardo Kratje, Claudio Prieto
Applied Microbiology and Biotechnology.2022; 106(2): 579. CrossRef
Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery
Audrey Olshefsky, Christian Richardson, Suzie H. Pun, Neil P. King
Bioconjugate Chemistry.2022; 33(11): 2018. CrossRef
Can Virus-like Particles Be Used as Synergistic Agent in Pest Management?
Caroline Deshayes, Anne-Sophie Gosselin-Grenet, Mylène Ogliastro, Bruno Lapied, Véronique Apaire-Marchais
Viruses.2022; 14(5): 943. CrossRef
Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
Hasnat Tariq, Sannia Batool, Saaim Asif, Mohammad Ali, Bilal Haider Abbasi
Frontiers in Microbiology.2022;[Epub] CrossRef
Development and characterization of monoclonal antibodies against red-spotted grouper nervous necrosis virus and their neutralizing potency in vitro
Zhiqi Zhang, Jing Xing, Xiaoqian Tang, Xiuzhen Sheng, Heng Chi, Wenbin Zhan
Aquaculture.2022; 560: 738562. CrossRef
Sendai virus particles carrying target virus glycoproteins for antibody induction
Hiroshi Ishii, Midori Nakamura-Hoshi, Tsugumine Shu, Tetsuro Matano
Vaccine.2022; 40(16): 2420. CrossRef
Emerging Frontiers in Vaccine Development: A Review of Changing Paradigm
Ishan Ghosh, Mohit D. Gandhi
Journal of Biosciences and Medicines.2022; 10(07): 123. CrossRef
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Alessio Facciolà, Giuseppa Visalli, Antonio Laganà, Angela Di Pietro
Vaccines.2022; 10(5): 819. CrossRef
RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform
Beom Jeung Hwang, Yohan Jang, Soon Bin Kwon, Ji Eun Yu, Jongkwan Lim, Young Hoon Roh, Baik L. Seong
Biomaterials.2021; 269: 120650. CrossRef
Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery
Kingshuk Dutta, Ritam Das, Jewel Medeiros, S. Thayumanavan
Biochemistry.2021; 60(13): 966. CrossRef
Engineering Tobacco Mosaic Virus and Its Virus‐Like‐Particles for Synthesis of Biotemplated Nanomaterials
Kok Zhi Lee, Vindula Basnayake Pussepitiyalage, Yu‐Hsuan Lee, L. Sue Loesch‐Fries, Michael T. Harris, Shohreh Hemmati, Kevin V. Solomon
Biotechnology Journal.2021;[Epub] CrossRef
Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
Ester Calvo Fernández, Lucie Y. Zhu
British Journal of Clinical Pharmacology.2021; 87(9): 3408. CrossRef
Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
Halle Lutz, Kristen D. Popowski, Phuong-Uyen C. Dinh, Ke Cheng
Advanced NanoBiomed Research.2021;[Epub] CrossRef
RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform
Jongkwan Lim, Yucheol Cheong, Young-Seok Kim, Wonil Chae, Beom Jeung Hwang, Jinhee Lee, Yo Han Jang, Young Hoon Roh, Sang-Uk Seo, Baik L. Seong
Nanomedicine: Nanotechnology, Biology and Medicine.2021; 37: 102438. CrossRef
Nano-based approaches in the development of antiviral agents and vaccines
Yang Li, Yushuo Xiao, Yuchen Chen, Kun Huang
Life Sciences.2021; 265: 118761. CrossRef
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers
Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, Camellia Katalani, Abbas Hajizade, Andrew J. Easton, Gholamreza Ahmadian
Journal of Nanobiotechnology.2021;[Epub] CrossRef
VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases
Aline Maria Vasconcelos Queiroz, Johny Wysllas de Freitas Oliveira, Cláudia Jassica Moreno, Diego M. A. Guérin, Marcelo Sousa Silva
Vaccines.2021; 9(3): 220. CrossRef
Nervous Necrosis Virus-like Particle (VLP) Vaccine Stimulates European Sea Bass Innate and Adaptive Immune Responses and Induces Long-Term Protection against Disease
Sofie Barsøe, Kerstin Skovgaard, Dagoberto Sepúlveda, Ansgar Stratmann, Niccolò Vendramin, Niels Lorenzen
Pathogens.2021; 10(11): 1477. CrossRef
Long-Term Protection and Serologic Response of European Sea Bass Vaccinated with a Betanodavirus Virus-Like Particle Produced in Pichia pastoris
Sofie Barsøe, Anna Toffan, Francesco Pascoli, Ansgar Stratmann, Tobia Pretto, Andrea Marsella, Mériem Er-Rafik, Niccolò Vendramin, Niels J. Olesen, Dagoberto Sepúlveda, Niels Lorenzen
Vaccines.2021; 9(5): 447. CrossRef
Expression, Purification, and Characterization of Bovine Leukemia Virus-Like Particles Produced in Drosophila S2 Cells
Natalia Olivero-Deibe, Lorena Tomé-Poderti, Federico Carrión, Sergio Bianchi, Martín Fló, Daniel Prieto, Florencia Rammauro, Andrés Addiego, Natalia Ibañez, Madelón Portela, Rosario Duran, Mabel Berois, Otto Pritsch
Frontiers in Virology.2021;[Epub] CrossRef
Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines
Acharya Balkrishna, Vedpriya Arya, Akansha Rohela, Ashwani Kumar, Rachna Verma, Dinesh Kumar, Eugenie Nepovimova, Kamil Kuca, Naveen Thakur, Nikesh Thakur, Pankaj Kumar
Vaccines.2021; 9(10): 1129. CrossRef
Baculovirus affinity removal in viral-based bioprocesses
Mafalda G. Moleirinho, Rita P. Fernandes, Sofia B. Carvalho, Sandra Bezemer, Frank Detmers, Pim Hermans, Ricardo J.S. Silva, Paula M. Alves, Manuel J.T. Carrondo, Cristina Peixoto
Separation and Purification Technology.2020; 241: 116693. CrossRef
Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
Naru Zhang, Chaoqun Li, Shibo Jiang, Lanying Du
Vaccines.2020; 8(3): 481. CrossRef
A Flow-Through Chromatographic Strategy for Hepatitis C Virus-Like Particles Purification
Ricardo J. S. Silva, Mafalda G. Moleirinho, Ana S. Moreira, Alex Xenopoulos, Paula M. Alves, Manuel J. T. Carrondo, Cristina Peixoto
Processes.2020; 8(1): 85. CrossRef
Virus-like particle vaccine displaying Toxoplasma gondii apical membrane antigen 1 induces protection against T. gondii ME49 infection in mice
Min-Ju Kim, Su-Hwa Lee, Hae-Ji Kang, Ki-Back Chu, Hyunwoo Park, Hui Jin, Eun-Kyung Moon, Sung Soo Kim, Fu-Shi Quan
Microbial Pathogenesis.2020; 142: 104090. CrossRef
Bacterial Production of Barley Stripe Mosaic Virus Biotemplates for Palladium Nanoparticle Growth
Yu-Hsuan Lee, Kok Zhi Lee, Rachel G. Susler, Corren A. Scott, Longfei Wang, L. Sue Loesch-Fries, Michael T. Harris, Kevin V. Solomon
ACS Applied Nano Materials.2020; 3(12): 12080. CrossRef
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
Carlotta Biagi, Arianna Dondi, Sara Scarpini, Alessandro Rocca, Silvia Vandini, Giulia Poletti, Marcello Lanari
Vaccines.2020; 8(4): 672. CrossRef
Virus-like particle-display of the enterotoxigenic Escherichia coli heat-stable toxoid STh-A14T elicits neutralizing antibodies in mice
Morten L. Govasli, Yuleima Diaz, Pål Puntervoll
Vaccine.2019; 37(43): 6405. CrossRef
Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications
Alexandra N. Tsoras, Julie A. Champion
Annual Review of Chemical and Biomolecular Engineering.2019; 10(1): 337. CrossRef
Capsid containing virus like particle vaccine against Zika virus made from a stable cell line
Himanshu Garg, Tugba Mehmetoglu-Gurbuz, Gregory M. Ruddy, Anjali Joshi
Vaccine.2019; 37(48): 7123. CrossRef
Incorporation of CD40 ligand enhances the immunogenicity of tumor‑associated calcium signal transducer 2 virus‑like particles against lung cancer
Wang Xi, Dong Ke, Long Min, Wang Lin, Zuo Jiahui, Lin Fang, Gao Zhaowei, Zhang Zhe, Chen Xi, Zhang Huizhong
International Journal of Molecular Medicine.2018;[Epub] CrossRef
Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles
Young-Seok Kim, Ahyun Son, Jihoon Kim, Soon Bin Kwon, Myung Hee Kim, Paul Kim, Jieun Kim, Young Ho Byun, Jemin Sung, Jinhee Lee, Ji Eun Yu, Chan Park, Yeon-Sook Kim, Nam-Hyuk Cho, Jun Chang, Baik L. Seong
Frontiers in Immunology.2018;[Epub] CrossRef
Nanoparticle vaccines against viral infections
Fernando B. Sulczewski, Raquel B. Liszbinski, Pedro R. T. Romão, Luiz Carlos Rodrigues Junior
Archives of Virology.2018; 163(9): 2313. CrossRef
Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71
Xi Wang, Ke Dong, Min Long, Fang Lin, Zhaowei Gao, Lin Wang, Zhe Zhang, Xi Chen, Ying Dai, Huiping Wang, Huizhong Zhang
Archives of Virology.2018; 163(7): 1851. CrossRef
Questions of bioethics and biosafety in the problem of biotechnology and use of vaccine for prevention of human infectious diseases
V. Zadorozhna, N. Vynnyk
Bulletin "Veterinary biotechnology".2018; 32(1): 459. CrossRef
MultiBac: from protein complex structures to synthetic viral nanosystems
Martin Pelosse, Hannah Crocker, Barbara Gorda, Paul Lemaire, Jens Rauch, Imre Berger
BMC Biology.2017;[Epub] CrossRef
Green Tea Catechin-Inactivated Viral Vaccine Platform
Yun H. Lee, Yo H. Jang, Young H. Byun, Yucheol Cheong, Paul Kim, Young J. Lee, Yoon J. Lee, Je M. Sung, Ahyun Son, Hye M. Lee, Jinhee Lee, Seung W. Yang, Jae-Min Song, Baik L. Seong
Frontiers in Microbiology.2017;[Epub] CrossRef
Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus
Himanshu Garg, Melina Sedano, Gabrielle Plata, Erin B. Punke, Anjali Joshi, Michael S. Diamond
Journal of Virology.2017;[Epub] CrossRef

Research Support, Non-U.S. Gov'ts

Function of VP2 Protein in the Stability of the Secondary Structure of Virus-like Particles of Genogroup II Norovirus at Different pH Levels: Function of VP2 Protein in the Stability of NoV VLPs: Yao Lin , Li Fengling , Wang Lianzhu , Zhai Yuxiu , Jiang Yanhua; J. Microbiol. 2014;52(11):970-975. Published online October 3, 2014; DOI: https://doi.org/10.1007/s12275-014-4323-6

54 View
0 Download
32 Crossref

Abstract

VP2 is the minor structural protein of noroviruses (NoV) and may function in NoV particle stability. To determine the function of VP2 in the stability of the NoV particle, we constructed and purified two kinds of virus-like particles (VLPs), namely, VLPs (VP1) and VLPs (VP1+VP2), from Sf9 cells infected with recombinant baculoviruses by using a Bac-to-Bac? baculovirus expression system. The two kinds of VLPs were treated with different phosphate buffers (pH 2 to pH 8); the secondary structure was then analyzed by far UV circular dichroism (CD) spectroscopy. Results showed that significant disruptions of the secondary structure of proteins were not observed at pH 2 to pH 7. At pH 8, the percentages of α-helix, β-sheet, and β-turn in VLPs (VP1) were decreased from 11% to 8%, from 37% to 32%, and from 20% to 16%, respectively. The percentage of coil was increased from 32% to 44%. By contrast, the percentages of α-helix, β-sheet, and β-turn in VLPs (VP1+VP2) were decreased from 11% to 10%, from 37% to 35%, and from 20% to 19%, respectively. The percentage of coil was increased from 32% to 36%. VLPs (VP1+VP2) was likely more stable than VLPs (VP1), as indicated by the percentage of the secondary structures analyzed by CD. These results suggested that VP2 could stabilize the secondary structure of VLPs under alkaline pH conditions. This study provided novel insights into the molecular mechanism of the function of VP2 in the stability of NoV particles.

Citations

Citations to this article as recorded by

Genomic diversity and comparative phylogenomic analysis of genus Norovirus
Huijeong Doh, Changhyeon Lee, Nam Yee Kim, Yun-Yong Park, Eun-jeong Kim, Changsun Choi, Seong-il Eyun
Scientific Reports.2025;[Epub] CrossRef
Progress and challenges in thermal inactivation of norovirus in oysters
Razieh Sadat Mirmahdi, Naim Montazeri
Critical Reviews in Food Science and Nutrition.2025; : 1. CrossRef
Advances in human norovirus research: Vaccines, genotype distribution and antiviral strategies
JunLi Chen, ZhengChao Cheng, Jing Chen, Lingling Qian, Haoran Wang, YuWei Liu
Virus Research.2024; 350: 199486. CrossRef
GII.6 norovirus major capsid protein VP1 derived from distinct clusters induce cross-blocking effects
Jie Ma, Jinjin Liu, Chaohong Fu, Yuqi Huo
Infection, Genetics and Evolution.2024; 122: 105617. CrossRef
Production of infectious reporter murine norovirus by VP2 trans -complementation
Ryoka Ishiyama, Kazuhiro Yoshida, Kazuki Oikawa, Reiko Takai-Todaka, Akiko Kato, Kumiko Kanamori, Akira Nakanishi, Kei Haga, Kazuhiko Katayama, Christiane E. Wobus
Journal of Virology.2024;[Epub] CrossRef
Out-of-sync evolutionary patterns and mutual interplay of major and minor capsid proteins in norovirus GII.2
Ruiquan Xu, Liang Xue, Jingmin Wang, Yiqing Chen, Yingwen Cao, Junshan Gao, Hui Gao, Qingyao Du, Xiaoxia Kou, Lin Yu
Journal of General Virology .2024;[Epub] CrossRef
Characteristics of Norovirus capsid protein-specific CD8 + T-Cell responses in previously infected individuals
Taojun He, Yilin Deng, Fang Zhang, Jin Zhang, Luhong Zhu, Qinjin Wang, Jie Ning, Hui Wu, Hanmei Yuan, Bin Li, Chao Wu
Virulence.2024;[Epub] CrossRef
Near-atomic structures of RHDV reveal insights into capsid assembly and different conformations between mature virion and VLP
Zhiyang Ruan, Qianqian Shao, Yanhua Song, Bo Hu, Zhiyu Fan, Houjun Wei, Yunshu Liu, Fang Wang, Qianglin Fang, Christiane E. Wobus
Journal of Virology.2024;[Epub] CrossRef
High yield production of norovirus GII.4 virus-like particles using silkworm pupae and evaluation of their protective immunogenicity
Akitsu Masuda, Jae Man Lee, Takeshi Miyata, Shintaro Sato, Atsushi Masuda, Masahiro Taniguchi, Ryosuke Fujita, Hiroshi Ushijima, Keisuke Morimoto, Takeru Ebihara, Masato Hino, Kohei Kakino, Hiroaki Mon, Takahiro Kusakabe
Vaccine.2023; 41(3): 766. CrossRef
Biological and physico-chemical characterization of human norovirus-like particles under various environmental conditions
Nicole Abou-Hamad, Marie Estienney, Rémi Chassagnon, Marjorie Bon, Philippe Daval-Frerot, Alexis de Rougemont, Stéphane Guyot, Frédéric Bouyer, Gaël Belliot
Colloids and Surfaces B: Biointerfaces.2023; 231: 113545. CrossRef
Linear epitopes on the capsid protein of norovirus commonly elicit high antibody response among past-infected individuals
Yilin Deng, Taojun He, Bin Li, Hanmei Yuan, Fang Zhang, Hui Wu, Jie Ning, Yanping Zhang, Aixia Zhai, Chao Wu
Virology Journal.2023;[Epub] CrossRef
Development and efficacy evaluation of remodeled canine parvovirus-like particles displaying major antigenic epitopes of a giant panda derived canine distemper virus
Shan Zhao, Xinfeng Han, Yifei Lang, Yue Xie, Zhijie Yang, Qin Zhao, Yiping Wen, Jing Xia, Rui Wu, Xiaobo Huang, Yong Huang, Sanjie Cao, Jingchao Lan, Li Luo, Qigui Yan
Frontiers in Microbiology.2023;[Epub] CrossRef
Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters
Camilla A. Strother, Paul D. Brewer-Jensen, Sylvia Becker-Dreps, Omar Zepeda, Samantha May, Fredman Gonzalez, Yaoska Reyes, Benjamin D. McElvany, April M. Averill, Michael L. Mallory, Anna M. Montmayeur, Verónica P. Costantini, Jan Vinjé, Ralph S. Baric,
Frontiers in Immunology.2023;[Epub] CrossRef
The VP2 protein exhibits cross-interaction to the VP1 protein in norovirus GII.17
Yingyin Liao, Linping Wang, Xiaojing Hong, Junshan Gao, Yueting Zuo, Yanhui Liang, Yueting Jiang, Jumei Zhang, Aiwu Wu, Liang Xue, Xiaoxia Kou
Infection, Genetics and Evolution.2022; 100: 105265. CrossRef
Epochal Coevolution of Minor Capsid Protein in Norovirus Gii.4 Variants with Major Capsid Protein Based on Their Interactions Over the Last Five Decades
Xiaoxia Kou, Xiaojing Hong, Liang Xue, Junshan Gao, Yueting Jiang
SSRN Electronic Journal .2022;[Epub] CrossRef
First Detection and Genomic Characterization of Bovine Norovirus from Yak
Yuchen Cui, Xi Chen, Hua Yue, Cheng Tang
Pathogens.2022; 11(2): 192. CrossRef
Atomic Structure of the Human Sapovirus Capsid Reveals a Unique Capsid Protein Conformation in Caliciviruses
Naoyuki Miyazaki, Chihong Song, Tomoichiro Oka, Motohiro Miki, Kosuke Murakami, Kenji Iwasaki, Kazuhiko Katayama, Kazuyoshi Murata, Rebecca Ellis Dutch
Journal of Virology.2022;[Epub] CrossRef
Noroviruses—The State of the Art, Nearly Fifty Years after Their Initial Discovery
Louisa F. Ludwig-Begall, Axel Mauroy, Etienne Thiry
Viruses.2021; 13(8): 1541. CrossRef
Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine
Wei Chen, Tao Kang, Rongliang Yuan, Congwen Shao, Shenrong Jing
Biotechnology Letters.2020; 42(7): 1211. CrossRef
Review Norovirus
Kazuhiko KATAYAMA
Uirusu.2020; 70(2): 117. CrossRef
Characterization of the complete genome sequence of the recombinant norovirus GII.P16/GII.4_Sydney_2012 revealed in Russia
E. V. Zhirakovskaia, A. Y. Tikunov, S. N. Sokolov, B. I. Kravchuk, E. I. Krasnova, N. V. Tikunova
Vavilov Journal of Genetics and Breeding.2020; 24(1): 69. CrossRef
Human Norovirus Proteins: Implications in the Replicative Cycle, Pathogenesis, and the Host Immune Response
Claudia P. Campillay-Véliz, Jonatan J. Carvajal, Andrea M. Avellaneda, Darling Escobar, Camila Covián, Alexis M. Kalergis, Margarita K. Lay
Frontiers in Immunology.2020;[Epub] CrossRef
Genomics Analyses of GIV and GVI Noroviruses Reveal the Distinct Clustering of Human and Animal Viruses
Lauren A. Ford-Siltz, Lisa Mullis, Yasser M. Sanad, Kentaro Tohma, Cara J. Lepore, Marli Azevedo, Gabriel I. Parra
Viruses.2019; 11(3): 204. CrossRef
Prevalence and complete genome of bovine norovirus with novel VP1 genotype in calves in China
Yuelin Wang, Hua Yue, Cheng Tang
Scientific Reports.2019;[Epub] CrossRef
The coordinating role of the human norovirus minor capsid protein VP2 is essential to functional change and nuclear localization of the major capsid protein VP1
Zhili Liu, Min Zhang, Zhen Shen, Huifen Chen, Wanju Zhang, Xiaoqing Xu, Zelin Lai, Wenqin Sun, Zheng Zhao, Jun Zhang
Archives of Virology.2019; 164(4): 1173. CrossRef
Free-Chlorine Disinfection as a Selection Pressure on Norovirus
Andri Taruna Rachmadi, Masaaki Kitajima, Kozo Watanabe, Sakiko Yaegashi, Joeselle Serrana, Arata Nakamura, Toyoko Nakagomi, Osamu Nakagomi, Kazuhiko Katayama, Satoshi Okabe, Daisuke Sano, Christopher A. Elkins
Applied and Environmental Microbiology.2018;[Epub] CrossRef
Norovirus assembly and stability
Ronja Pogan, Jasmin Dülfer, Charlotte Uetrecht
Current Opinion in Virology.2018; 31: 59. CrossRef
pH-Dependence of RNA Extraction for Norovirus by TRIzol Method
Deok-Young Jhon
Journal of Food Hygiene and Safety.2018; 33(1): 71. CrossRef
Persistence and Elimination of Human Norovirus in Food and on Food Contact Surfaces: A Critical Review
Nigel Cook, Angus Knight, Gary P. Richards
Journal of Food Protection.2016; 79(7): 1273. CrossRef
Norovirus mechanisms of immune antagonism
Alexa N Roth, Stephanie M Karst
Current Opinion in Virology.2016; 16: 24. CrossRef
Infection models of human norovirus: challenges and recent progress
Sangdo Ha, In-Soo Choi, Changsun Choi, Jinjong Myoung
Archives of Virology.2016; 161(4): 779. CrossRef
Norovirus Vaccines and Potential Antinorovirus Drugs: Recent Advances and Future Perspectives
Jacob Kocher, Lijuan Yuan
Future Virology.2015; 10(7): 899. CrossRef

The Production and Immunogenicity of Human Papillomavirus Type 58 Virus-like Particles Produced in Saccharomyces cerevisiae: Hye-Lim Kwag , Hyoung Jin Kim , Don Yong Chang , Hong-Jin Kim; J. Microbiol. 2012;50(5):813-820. Published online November 4, 2012; DOI: https://doi.org/10.1007/s12275-012-2292-1

46 View
0 Download
15 Scopus

Abstract: Human papillomavirus (HPV) is the cause of most cases of cervical cancer. HPV type 58 (HPV58) is the second most frequent cause of cervical cancer and high-grade squamous intraepithelial lesions (HSIL) in Asia and South / Central America, respectively. However, there is no vaccine against HPV58, although there are commercially available vaccines against HPV16 and 18. In this study, we produced HPV58 L1 protein from Saccharomyces cerevisiae, and investigated its immunogenicity. We first determined the optimum period of culture for obtaining HPV58 L1. We found that a considerable portion of the HPV58 L1 resulting from 48 h culture cannot be recovered by purification, while the HPV58 L1 resulting from 144 h culture is recovered efficiently: the yield of HPV58 L1 finally recovered from 144 h culture was 2.3 times higher than that from 48 h culture, although the production level of L1 protein from 144 h culture was lower than that from 48 h culture. These results indicate that the proportion of functional L1 protein from 144 h-cultured cells is significantly higher than that of 48 h-cultured cells. The HPV58 L1 purified from the 144 h culture was correctly assembled into structures similar to naturally occurring HPV virions. Immunization with the HPV58 L1 efficiently elicited anti-HPV58 neutralizing antibodies and antigen-specific CD4+ and CD8+ T cell proliferations, without the need for adjuvant. Our findings provide a convenient method for obtaining substantial amounts of highly immunogenic HPV58 L1 from S. cerevisiae.

First
Prev
Page of 1
Next
Last

Search